Navigation Links
Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
Date:6/4/2013

s B financing allows us to leverage our internal discovery engine, giving Protagonist the opportunity of having multiple internal and collaborative clinical assets by 2015-16."

About Protagonist Therapeutics
Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to explore the full potential of the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry-type analoging and SAR development.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and has discovery operations in Menlo Park, California USA and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.


'/>"/>
SOURCE Protagonist Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Protagonist Therapeutics Names David Liu Chief Scientific Officer
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Mass. , May 29, 2015  Haemonetics Corporation ... Davies , Chief Operating Officer, will present at the ... York on June 23 rd , 2015 ... may access Mr. Davies, presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/29/2015)... Calif. , May 29, 2015 ... data from two pivotal Phase 3, global, randomized, ... for the treatment of secondary hyperparathyroidism (SHPT) in ... Both studies met the primary endpoint, demonstrating that ... 416 groups achieved a greater than 30 percent ...
(Date:5/28/2015)... , May 28, 2015 Zimmer Holdings, Inc. ... has finalized agreements with buyers to divest in ... High-Flex Knee System assets, Biomet Discovery® Elbow System assets ... in furtherance of Zimmer,s pending acquisition of Biomet, Inc. ... continues to work constructively with the Bureau of Competition ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... PARIS , June 17 www.hra-pharma.com -HRA ... Advisory Committee for Reproductive Health Drugs voted 11 to 0 that ... is effective and safe for use as an emergency contraceptive. , ... The committee,s vote ...
... The balance of opportunities and activities in pharmaceutical market research is shifting ... , , , ... a strategic partner is if you provide interpretation and application of findings," explains a ... as value?" , , , ...
Cached Medicine Technology:FDA Advisory Committee Unanimously Recommends Approval of HRA Pharma's Ulipristal Acetate for Emergency Contraception 2FDA Advisory Committee Unanimously Recommends Approval of HRA Pharma's Ulipristal Acetate for Emergency Contraception 3Pharmaceutical Market Research: A Strategic Business Partner in 2011 2
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... team conducted research, choosing systems that have several awards ... healthcare leaders on what systems stood out to them ... considered for inclusion as well. , The 50 Great ... organizations: , Adventist Health System (Altamonte Springs, Fla.) , ...
(Date:5/29/2015)... A group of doctors have discovered “The ... effort to teach this “new math” to children in early ... “sickened” by the recent implementation of Common Core Math in ... Common Core is now a reality in children’s classrooms in ... now seeking ways to improve common core math training for ...
(Date:5/29/2015)... Inspire Nexus, a new social network officially launching June ... life coaches have asked, "How do I find coaching ... become a credentialed Coach?" , Many Life and Career ... Inspire Nexus, a social network for Coaches provides members ... experience coaching a certain number of hours, qualify to ...
(Date:5/29/2015)... York, NY (PRWEB) May 29, 2015 ... on the “beauty of protection”. Skin Health is ... USA Today within the markets of New York, Los ... an estimated 750,000 readers. Its digital counterpart will reach ... content hubs. To read more the Skin Health campaign ...
(Date:5/29/2015)... 2015 Shaila Jiwa, a physiotherapist from ... recently stated in a new announcement that patients of ... is commonly seen as a tabooed topic to talk ... physiotherapists like Shaila Jiwa try to encourage people to ... Incontinence is a condition that can be classified under ...
Breaking Medicine News(10 mins):Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2
... August ... ... collaboration with the Generic Pharmaceutical Association (GPhA), PhRMA, and the Consumer Healthcare Products Association ... Learned on SPL (August 11-12; Philadelphia, PA) , , , , ,The FDA ...
... Aon Consulting, the global human capital consulting organization of ... ), today announced that Paul Berger has joined the firm ... Practice. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) , ... segments to drive quality outcomes, wellness strategies and improved coordination ...
... Like clothing and hairstyles, oral piercings give teens and ... statement poses a number of potential oral and overall health ... most commonly involve the tongue, and also the lips, cheeks, ... implicated in a number of adverse oral and systemic conditions. ...
... OTC: CTYX) - Connectyx Technologies Holdings Group, Inc. announced recently ... July 9, 2009, at 4:15pm EDT. , ... will update shareholders and the financial community about the sales ... last six months, its initiatives to increase the market share ...
... , , , WASHINGTON, ... $500,000 grant to further the work of the National ... is nationally recognized amongst emergency managers and the disability ... dedicated emergency preparedness program and personnel experienced in emergency ...
... FOREST, Ill., July 9 ICU Medical, Inc., (Nasdaq: ... connectors, custom medical products and critical care devices, announced today ... acquire the commercial rights and physical assets of Hospira, Inc.,s ... approximately $35 million in cash. The acquisition is expected to ...
Cached Medicine News:Health News:DIA Workshop Features Industry and FDA for Discussion of Best Practices for Electronic Establishment Registration and Product Listing 2Health News:Chief Medical Officer Joins Aon Consulting's Health & Benefits Practice 2Health News:Chief Medical Officer Joins Aon Consulting's Health & Benefits Practice 3Health News:Oral Piercings Pose Potential Health Care Risks 2Health News:Oral Piercings Pose Potential Health Care Risks 3Health News:Connectyx Technologies Holdings Group, Inc. to Host Nationwide Teleconference Today, July 9, 2009; Company Will Discuss Recent Developments, New Partnerships and Initiatives for MedFlash EPHR, and Second Quarter Results 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 3Health News:ICU Medical, Inc. to Acquire Hospira's Critical Care Product Line 2Health News:ICU Medical, Inc. to Acquire Hospira's Critical Care Product Line 3Health News:ICU Medical, Inc. to Acquire Hospira's Critical Care Product Line 4Health News:ICU Medical, Inc. to Acquire Hospira's Critical Care Product Line 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: